Australia markets closed

Adaptive Biotechnologies Corporation (1HM.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
2.7050+0.1410 (+5.50%)
At close: 08:05AM CEST
Full screen
Previous close2.5640
Open2.7050
Bid2.7600 x N/A
Ask2.8170 x N/A
Day's range2.7050 - 2.7050
52-week range2.2140 - 8.0860
Volume67
Avg. volume0
Market cap426.492M
Beta (5Y monthly)1.24
PE ratio (TTM)N/A
EPS (TTM)-1.4600
Earnings date07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

    SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Ti

  • GlobeNewswire

    Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

    Announces CFO transitionSEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role. Strategic

  • GlobeNewswire

    Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

    SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business update conference call and webcast after market close on Tuesday, April 2, 2024 beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investor